Neuro-Oncology: An Emerging Neurologic Subspecialty in Thailand
Keywords:
Neuro-Oncology; Emerging; Neurologic; ThailandAbstract
No Abstract
References
1. Vaillant B, Kuo SH, de Groot J. Emerging subspecialties in neurology:
neuro-oncology: a developing subspecialty with many opportunities. Neurology.
2009 Mar;72(11):e51-3.
2. Sathornsumetee S, Reardon DA. High-grade astrocytoma. In: Norden AD,
Reardon DA, Wen PYC, ed. Primary central nervous system tumors:
Pathogenesis and therapy. New Jersey: Humana Press; 2011. p. 195-232.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn
MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005 Mar;352(10):987-96.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer
RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 2009 May;10(5):459-66.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature.
2008 Oct;455(7216):1061-8.
6. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma:
promise and challenge. Curr Pharm Des. 2007;13(35):3545-58.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. J Clin Oncol. 2009 Oct;27(28):4733-40.
8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase
II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan
at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009
Feb;27(5):740-5.
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon
DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J Clin Oncol. 2007 Oct;25(30):4722-9.
10. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE,
Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic
response and survival in malignant astrocytoma patients treated
with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan;26(2):271-8.
11. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies
for brain metastasis and complications from therapeutic techniques: a
review of current literature. Am J Clin Oncol. 2010 Aug;33(4):398-407.
12. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous
system. N Engl J Med. 2003 Oct;349(16):1543-54.
13. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar
JN, Boeve BF, et al. Positron emission tomography-computed tomography
in paraneoplastic neurologic disorders: systematic analysis and review.
Arch Neurol. 2010 Mar;67(3):322-9.
14. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies
to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul;77(2):
179-89.
neuro-oncology: a developing subspecialty with many opportunities. Neurology.
2009 Mar;72(11):e51-3.
2. Sathornsumetee S, Reardon DA. High-grade astrocytoma. In: Norden AD,
Reardon DA, Wen PYC, ed. Primary central nervous system tumors:
Pathogenesis and therapy. New Jersey: Humana Press; 2011. p. 195-232.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn
MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 2005 Mar;352(10):987-96.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer
RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide
versus radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 2009 May;10(5):459-66.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization
defines human glioblastoma genes and core pathways. Nature.
2008 Oct;455(7216):1061-8.
6. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma:
promise and challenge. Curr Pharm Des. 2007;13(35):3545-58.
7. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. J Clin Oncol. 2009 Oct;27(28):4733-40.
8. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase
II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan
at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009
Feb;27(5):740-5.
9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon
DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma
multiforme. J Clin Oncol. 2007 Oct;25(30):4722-9.
10. Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE,
Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic
response and survival in malignant astrocytoma patients treated
with bevacizumab and irinotecan. J Clin Oncol. 2008 Jan;26(2):271-8.
11. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies
for brain metastasis and complications from therapeutic techniques: a
review of current literature. Am J Clin Oncol. 2010 Aug;33(4):398-407.
12. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous
system. N Engl J Med. 2003 Oct;349(16):1543-54.
13. McKeon A, Apiwattanakul M, Lachance DH, Lennon VA, Mandrekar
JN, Boeve BF, et al. Positron emission tomography-computed tomography
in paraneoplastic neurologic disorders: systematic analysis and review.
Arch Neurol. 2010 Mar;67(3):322-9.
14. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies
to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul;77(2):
179-89.
Downloads
Published
03-04-2020
How to Cite
Sathornsumetee, S. . (2020). Neuro-Oncology: An Emerging Neurologic Subspecialty in Thailand. Siriraj Medical Journal, 63(5), 174–176. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/241003
Issue
Section
Special Issue
License
Authors who publish with this journal agree to the following conditions:
Copyright Transfer
In submitting a manuscript, the authors acknowledge that the work will become the copyrighted property of Siriraj Medical Journal upon publication.
License
Articles are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This license allows for the sharing of the work for non-commercial purposes with proper attribution to the authors and the journal. However, it does not permit modifications or the creation of derivative works.
Sharing and Access
Authors are encouraged to share their article on their personal or institutional websites and through other non-commercial platforms. Doing so can increase readership and citations.
